Oxidized mannan-MOG35-55 conjugate as a basis for targeted immune modulation in multiple sclerosis
By
Athanasia Mouzaki
Anne-Lise de Lastic
Vasso Apostolopoulos
Ioannis Matsoukas
April 28, 2026
Clinical Scorecard: Oxidized mannan-MOG35-55 conjugate as a basis for targeted immune modulation in multiple sclerosis
At a Glance
Category Detail
Condition Key Mechanisms Targeted modulation of antigen-specific immune responses through oxidized mannan-conjugated myelin oligodendrocyte glycoprotein peptide (OM-MOG35-55), enhanced by vitamin D3 conditioning. Target Population Care Setting
Key Highlights
OM-MOG35-55 enhances dendritic cell-mediated antigen presentation. Promotes expansion of regulatory T-cell populations and production of IL-10 and TGF-β1. Combining OM-MOG35-55 with vitamin D3 conditioning enhances immunomodulatory effects. Antigen-specific approach aims to restore immune tolerance without broad immunosuppression. Structural integrity of myelin proteins is crucial for immune recognition. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Long-term DMTs may lead to infections and malignancies; cautious interpretation of preclinical findings is necessary. Patient & Prescribing Data
OM-MOG35-55 shows promise in modulating immune responses without global immunosuppression for patients with autoreactive T-cell responses.
Clinical Best Practices
Utilize antigen-specific therapies to selectively silence pathogenic immune responses. Monitor for strain-specific differences in therapeutic efficacy. References
